2515-8163

Cephalalgia Reports

SAGE Publications

View prefix report (10.1177)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 80 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact80 DOIs
2

Add abstracts to 24 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact24 DOIs
3

Deposit reference lists for 8 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact8 DOIs

DOIs for this ISSN

Showing the top 5 of 265 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Burning mouth syndrome: An update (10.1177/2515816320970143)
ORCID
40.58 41
2 Efficacy and safety of galcanezumab for prevention of migrai… (10.1177/2515816320932573)
ORCID
39.21 36
3 Intentional avoidance of physical activity in women with mig… (10.1177/2515816318788284)
ORCID
32.53 19
4 Safety profile of a special butterbur extract from<i>Petasit… (10.1177/2515816318759304)
ORCID
31.38 17
5 A phase 1 randomized study of hemodynamic effects and pharma… (10.1177/25158163211007922)
ORCID
30.76 16
6 Rimegepant 75 mg for acute treatment of migraine is associat… (10.1177/25158163221075596)
ORCID
29.40 14
7 Targeted next generation sequencing identifies a genetic spe… (10.1177/2515816319881630)
ORCID
28.65 13
8 Long-term safety and efficacy of lasmiditan for acute treatm… (10.1177/2515816320958176)
ORCID
28.65 13
9 Clinical symptoms and results of autonomic function testing… (10.1177/2515816318773774)
ORCID
26.98 11
10 Patient-identified burden and unmet needs in patients with c… (10.1177/25158163221096866)
ORCID
26.03 10
11 Toward ICHD-4: Proposing a Broader Diagnostic Framework for… (10.1177/25158163251339141)
Abstract
26.03 10
12 Vestibular migraine presenting with acute peripheral vestibu… (10.1177/2515816320958175)
ORCID
25.00 9
13 Efficacy and safety of external trigeminal neurostimulation… (10.1177/2515816319856625)
ORCID
23.86 8
14 A systematic review of high-frequency transcranial magnetic… (10.1177/2515816319889971)
ORCID
23.86 8
15 Characteristics of migraine patients with Migraine Disabilit… (10.1177/2515816320928463)
ORCID
23.86 8
16 A century of bruxism research in top-ranking medical journal… (10.1177/25158163241235574)
ORCID
23.86 8
17 Muscle stiffness in tension-type headache patients with peri… (10.1177/2515816318760293)
ORCID
22.58 7
18 MENA 2020 Abstracts (10.1177/2515816320960387)
Abstract References ORCID
22.58 1
19 Translation and validation of an extended German version of… (10.1177/2515816320962773)
ORCID
22.58 7
20 Acute treatment of migraine with external trigeminal nerve s… (10.1177/2515816319829906)
ORCID
21.13 6
21 The effect of multiple doses of ubrogepant on the pharmacoki… (10.1177/2515816320905082)
ORCID
19.45 5
22 Early use of erenumab in US real-world practice (10.1177/25158163211020419)
ORCID
19.45 5
23 The quest for a headache pattern in giant cell arteritis: A… (10.1177/25158163211024134)
ORCID
19.45 5
24 Eptinezumab administered intravenously, subcutaneously, or i… (10.1177/25158163221131326)
ORCID
19.45 5
25 Evaluating the wearing-off effects of fremanezumab in high-f… (10.1177/25158163231207322)
ORCID
19.45 5
26 Comment on “Toward ICHD-4: Proposing a broader diagnostic fr… (10.1177/25158163251346956)
Abstract
19.45 5
27 Vasomotor reactions in the face and head of patients with mi… (10.1177/2515816318790543)
ORCID
17.47 4
28 Evaluation of the pharmacokinetic interaction and safety of… (10.1177/2515816320921186)
ORCID
17.47 4
29 Placebo response with subcutaneous injections in calcitonin… (10.1177/25158163221120103)
ORCID
17.47 4
30 Predictors of clinical response to erenumab in patients with… (10.1177/25158163221128185)
ORCID
17.47 4
31 Episodic unilateral mydriasis and recurrent headache (10.1177/2515816318772305)
Abstract ORCID
15.05 1
32 Restless legs syndrome is associated with increased risk of… (10.1177/2515816318780743)
ORCID
15.05 3
33 An unsuspected and unrecognized cause of medication overuse… (10.1177/2515816319897054)
ORCID
15.05 3
34 A triad of cluster-like headaches with delayed development o… (10.1177/2515816320911032)
ORCID
15.05 3
35 Headache in patients with Tourette syndrome: A systematic li… (10.1177/2515816320915711)
ORCID
15.05 3
36 Efficacy of galcanezumab in patients with episodic cluster h… (10.1177/25158163211015654)
ORCID
15.05 3
37 Comparative effectiveness of erenumab versus oral preventive… (10.1177/25158163211040061)
ORCID
15.05 3
38 Migrainous headaches, calcified cysticercosis and breakthrou… (10.1177/25158163221076464)
Abstract
15.05 3
39 Tolosa-Hunt syndrome after COVID-19 infection (10.1177/25158163221078977)
ORCID
15.05 3
40 The role of BDNF in the clinical course of primary headaches (10.1177/25158163231190292)
ORCID
15.05 3
41 Reply to Musella et al. (10.1177/25158163251346957)
Abstract
15.05 3
42 Oral dexamethasone for the prevention of acute migraine recu… (10.1177/2515816318804158)
ORCID
11.93 2
43 Dramatic response of intravenous lidocaine in a patient with… (10.1177/2515816318804816)
ORCID
11.93 2
44 Prediction of the sphenopalatine ganglion localization in co… (10.1177/2515816318824690)
ORCID
11.93 2
45 Clinical profile of SUNCT/SUNA in Japan: A clinic-based stud… (10.1177/2515816319829907)
ORCID
11.93 2
46 Isolated headache and its association with characteristics a… (10.1177/2515816320919961)
ORCID
11.93 2
47 Can the effects of the mitochondrial DNA mutations found in… (10.1177/2515816320939571)
ORCID
11.93 2
48 Effects of CYP3A4 and P-glycoprotein inhibition or induction… (10.1177/25158163211037344)
ORCID
11.93 2
49 Rimegepant as an acute treatment in a refractory migraine pa… (10.1177/25158163241235130)
ORCID
11.93 2
50 Reversible cerebral vasoconstriction syndrome developed duri… (10.1177/25158163241259108)
ORCID
11.93 2